Biologic switching patterns in psoriasis reveal the real-world durability gap

Reading the signal

Psoriasis biologic registries across multiple markets (PsoBest, PSOLAR, BADBIR) capture treatment outcomes over years rather than the 16 to 52 weeks of pivotal trials. The picture from these registries is consistent across markets: switch rates at three years are higher than the pivotal trial efficacy data would predict, and switch rates at five years are higher still.

The drivers are familiar:

• Durability of response over time: skin clearance achieved at 16 weeks is not always maintained at 52 weeks or beyond, even on continuous therapy
• Secondary loss of efficacy: anti-drug antibody development affects some classes more than others; the patient-level prediction is poor
• Patient-experience factors: injection burden, dosing frequency, and the overall biologic-experience story drive switches that the trials cannot capture

The class differences in real-world durability do not always match the class differences in pivotal trial efficacy. IL-17 and IL-23 inhibitor classes show stronger real-world durability than TNF in late-line use; IL-23 in particular has emerged as a real-world durability winner in registry data.

Commercial implications

For sponsors of psoriasis biologics and adjacent immunology assets:

1. Real-world durability is becoming the primary differentiation axis as the biologic class matures. When pivotal efficacy is broadly comparable across the class, durability is what swings the second and third-line decision.
2. The patient-experience layer is now a commercial input, not a marketing one. Injection burden, dosing frequency, and the overall regimen experience matter for switching, and assets with differentiated patient-experience profiles benefit accordingly.
3. Real-world evidence generation is now a commercial necessity in psoriasis, not a post-launch optimisation. Registry participation, real-world cohort generation, and the analytics infrastructure to read it are commercial assets.

What we are watching

• Five-year and ten-year real-world durability data from the major registries as the IL-23 and IL-17 classes accumulate longer follow-up
• Switch-pattern data and the cumulative evidence base on what drives each switch decision
• Commercial responses: sponsors that position on real-world durability rather than pivotal trial efficacy in the first-line conversation